Date: Wednesday 14 February 2024
Time: 16:00-17:30 CET /15:00-16:30 GMT

Programme: New perspectives in Congenital Hyperinsulinism
• Welcome & introduction
Dr Senthil Senniappan (Liverpool, UK) – ESPE Connect Webinar Convenor
• Diagnosis and management
Dr Senthil Senniappan
• Parent and family perspectives of CHI
Julie Raskin - CEO, Congenital Hyperinsulinism International (New Jersey, USA)
• New advances of CHI
Professor Klaus Mohnike (Magdeburg, Germany)
• Panel Discussion
• Webinar Close
Dr Senthil Senniappan

Learn more about our expert speakers

Dr Senthil Senniappan (Liverpool, UK)
Dr Senthil Senniappan is the Clinical Director for Endocrinology at Alder Hey Children’s Hospital, Liverpool, UK, and an honorary Associate Professor at University of Liverpool. Dr Senniappan underwent endocrine training initially at Royal Manchester Children’s Hospital and subsequently at Great Ormond Street Hospital, London, where he completed his PhD in congenital hyperinsulinism. Dr Senniappan has special interest in congenital hyperinsulinism, obesity, andrology, and growth disorders. Dr Senniappan leads the complex obesity MDT service (CEW) and co-leads the NSHE Commissioned Quaternary congenital hyperinsulinism (CHI) service. He is supported by a team of dedicated multidisciplinary professionals including dieticians, psychologists, clinical and research fellows, physiotherapists, social worker, and specialist nurses.


Dr Senniappan is research active and leads several clinical trials and supervises research fellows and students. He has published around 80 peer reviewed PubMed index articles including publications in NEJM and Human Molecular Genetics and several book chapters.

Dr Senniappan is the secretary elect for BSPED (British Society for Paediatric Endocrinology & Diabetes). He was previously the CME officer and POC chair for BSPED and has contributed to RCPCH as Quality advisor for Endocrinology CSAC and MRCPCH Examiner. Dr Senniappan has active roles in ESPE as webinar convenor and Chair of the ESPE clinical fellowship committee.

Julie Raskin (New Jersey, USA)
After Julie’s son Ben was born with congenital hyperinsulinism (HI), a condition that causes the overproduction of insulin that leads to severe hypoglycemia, Julie joined a dedicated group of parents whose children were also affected by the condition to found Congenital Hyperinsulinism International (CHI). Julie is the CEO of CHI and since 2010 she has led this active worldwide community of patients, their families and caregivers, expert clinicians and researchers, and professionals in the biotech field to fulfil CHI’s mission to find better treatments, prevent death and brain damage, and support HI families every step of the way.

Professor Klaus Mohnike (Magdeburg, Germany)
Professor Klaus Mohnike is a paediatric endocrinologist based at Children’s Hospital, Otto-von-Guericke-University Magdeburg, Germany. His main clinical expertise and research activities are related to bone dysplasia and congenital hyperinsulinism. He specialises in metabolic and endocrine disorders and is chair of the Central-German Network for Rare Diseases (Mitteldeutsche Kompetenznetz für Seltene Erkrankungen (MKSE)).
Professor Mohnike is coordinator of the Center of excellence 'Collaborative alliance for congenital hyperinsulinism (COACH)' and represents the OvGU in the European reference networks (ERN) Endo-ERN, Metab-ERN and ERN-BOND.

Over the last 20 years he developed inter-institutional registries for different rare diseases (bone dysplasia, congenital hyperinsulinism, congenital adrenal hyperplasia) to establish tools for quality assurance in medicine. He has published more than 135 scientific publications in international journals and book chapters.